UAE Approves Use of Sinopharm Vaccine for 3-17 Years Children

  • Publish date: Monday، 02 August 2021
UAE Approves Use of Sinopharm Vaccine for 3-17 Years Children

The Ministry of Health and Prevention (MoHAP) has approved the emergency use of the Sinopharm vaccine for 3 to 17 age group, based on the results of clinical studies, the strict assessment to approve the emergency use of the vaccine and the local evaluation that complies with the approved regulations.

The approval for the vaccine comes as part of the UAE's efforts to combat the COVID-19 virus, and an affirmation of its proactive approach to ensure the health and safety of community members.

The study had enrolled, with full parental consent, a total of 900 children aged between three and 17 years old. It was launched in June (2021), and was the first project in the Middle East and North Africa region designed to study young children’s immune response to being inoculated against COVID-19.

Children of different nationalities were enrolled, administered Sinopharm vaccine doses, and closely monitored over the following weeks.

The roll-out of the vaccine for this age group in the UAE is likely to support a safer return to school for many children in September, especially as COVID-19 variants increase infection rates worldwide.

Till date, the UAE had provided Pfizer COVID-19 vaccines to only children aged 12 years and older, and this will therefore be the first chance for residents to vaccinate younger children against COVID-19.

The UAE has so far administered more than 15.5 million doses of COVID-19 vaccines, with more than 64% of the population having received more than two doses till date.